Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
Locoregionally advanced mucosal melanoma, particularly when harboring the BRAF V600L mutation and situated in the hypopharynx, presents a therapeutic challenge due to limited treatment options and aggressive behavior. Traditional modalities often yield unsatisfactory outcomes, prompting the explorat...
Saved in:
Main Author: | Sivakamavalli Jeyachandran |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-06-01
|
Series: | Oral Oncology Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024003777 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysis
by: Jianhao Bai, et al.
Published: (2025-01-01) -
Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study
by: Malte Beckmann, et al.
Published: (2024-11-01) -
Melanoma genomics – will we go beyond BRAF in clinics?
by: Justyna Mirek, et al.
Published: (2024-09-01) -
RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATION
by: Bello Abdullahi Umar, et al.
Published: (2019-12-01) -
Systemic therapy of skin metastatic melanoma with BRAF gene mutation
by: Yu. S. Shakh-Paronyants, et al.
Published: (2023-03-01)